Slide Your Biology, Your Decision® preludedx dcisionrt logo Click to scroll What is your DCISion Score?

DCISionRT, the Only DCIS Test to Predict Radiation Therapy Benefit

PreludeDx Genesis world
Increasing Patient Access to DCISionRT with GenesisCare

 Increasing Patient Access to DCISionRT

Click for Info

Important DCISionRT Information for Physicians and Patients

  • Dr. Anushka Patel
  • Dr. Christy Kesslering

For Doctors

The Test

For Patients

preludedx dcisionrt logo

The DCIS Test That Enables Personalized Treatment

dcisionrt personalized treatment vertical

DCISionRT enables physicians to deliver precision medicine to DCIS patients

In a multisite study including 474 DCIS patients, DCISionRT substantially reclassified DCIS patient risk compared to traditional clinicopathologic risk assessment, such as grade (shown). In fact, 53% of patients with low or intermediate grade DCIS (grade 1 or 2) were upstaged to elevated risk by DCISionRT and 30% of patients with high grade DCIS (grade 3) were identified as low risk by DCISionRT1. With DCISionRT, patients and physicians have access to a test that enables truly personalized treatment based on a patient’s individual biology.
Traditional risk assessment using DCIS grade to DCISionRT risk groups indicates the power of the DCISionScore. While traditional risk assessment with DCIS grade shows little difference for low/intermediate grade DCIS (grade 1 & 2) compared to high grade DCIS, DCISionRT distinguishes which patients have a clinically low risk (DCISionScore ≤3) from those with clinically elevated risk (DCISionScore >3). With DCISionRT, Know Your Risk™.

Results are shown are for the 196 patients treated with conserving surgery treated patients with clear margins in a multisite study. Total recurrence risks shown are adjusted for year of diagnosis. This was demonstrated in a multisite study of 474 patients1.

1 Bremer T, Whitworth P, Patel R, et al. . A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res . 2018; doi:10.1158/1078-0432.CCR-18-0842.